Drug intelligence / Profile preview

OC201

Development stage: Preclinical
Lead developer: Oncocross
Modality: Small Molecules

Overview

OC201 is an AI-driven therapeutic candidate developed by Oncocross Co., Ltd. using its RAPTOR AI platform. It is being investigated for the treatment of pancreatic cancer, specifically to enhance the efficacy of the FOLFIRINOX chemotherapy regimen and suppress metastasis. OC201 functions by modulating the Hypoxia-inducible factor 1-alpha (HIF-1α) pathway and the epithelial-mesenchymal transition (EMT)-stemness axis. Preclinical studies have demonstrated that OC201, particularly when used in combination with OC202e, reduces the expression of stemness markers such as CD44 and Flotillin2, thereby overcoming multidrug resistance and reducing metastatic burden in hepatic models.

Targets

AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on OC201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC201.

Explore the full profile